BC Extra | Jan 17, 2020
Preclinical News

Jan 16 Preclinical Quick Takes: Deerfield's Orchard partners with Yeda; Acuitas-Penn flu vaccine in newborns; plus Regeneron, Genentech-Gladstone and Banyan

Deerfield forms Orchard Innovations in Yeda collaboration on translation  Deerfield Management Co. launched Orchard Innovations LLC to pursue translational R&D derived from Weizmann Institute of Science research. Yeda Research and Development Co. Ltd., Weizmann’s commercial...
BC Extra | Sep 13, 2019
Clinical News

Sept. 13 Clinical Quick Takes: Amgen, Atara, MS biomarkers and switching in psoriasis

Clinical holds on two Amgen trials for cardiac safety signal   Amgen (NASDAQ:AMGN) said FDA placed a clinical hold on a Phase I trial of MCL1 inhibitor AMG 397 “to evaluate a safety signal for...
BC Innovations | May 7, 2019
Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Gene expression profiling in neurons, oligodendrocytes, microglia and other CNS cell types could help diagnose early Alzheimer's disease. In post-mortem prefrontal cortex samples AD patient and unaffected...
BC Innovations | Dec 4, 2018
Distillery Therapeutics


INDICATION: Alzheimer's disease (AD) In vitro and mouse studies identified an inhibitor of Aβ 42 polymerization that could help treat AD. In vitro screening of nine amyloid-binding compounds in polymerization assays, followed by in vitro...
BC Week In Review | Aug 3, 2018
Clinical News

Banyan reports 97.6% sensitivity for TBI diagnostic

Banyan Biomarkers Inc. (Alachua, Fl.) said data from the ALERT-TBI study showed that its blood-based diagnostic Banyan BTI had 97.6% sensitivity and a 99.6% negative predictive value (NPV) for detecting intracranial injury to rule out...
BC Week In Review | Feb 16, 2018
Clinical News

FDA approves Banyan's brain trauma blood test

FDA approved the Banyan Brain Trauma Indicator (BTI) from Banyan Biomarkers Inc. (Alachua, Fla.) as an in vitro diagnostic blood test to aid in the evaluation of adults with suspected mild traumatic brain injury (TBI)....
BC Innovations | Feb 15, 2017
Distillery Therapeutics


INDICATION: Alzheimer’s disease (AD) Mouse and monkey studies suggest inhibiting all forms of tau , not only hyperphosphorylated tau, could help treat AD and other tauopathies. In monkeys, an antisense oligonucleotide (ASO) against monkey tau decreased...
BC Innovations | Feb 18, 2016
Distillery Therapeutics

Therapeutics: Muscarinic acetylcholine receptor M1 (CHRM1; HM1); glial fibrillary acidic protein (GFAP)

Neurology INDICATION: Leukodystrophy Patient sample, fly and mouse studies suggest inhibiting CHRM1 could help treat Alexander disease, which is caused by GFAP mutations that result in impaired glial cell function. In postmortem patient brain tissue,...
BC Innovations | Sep 18, 2014
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Glioblastoma multiforme (GBM) circulating tumor cells (CTCs) to diagnose peripheral metastases Studies in patient samples suggest detecting CTCs could help diagnose extracranial GBM metastasis. In 29...
BC Week In Review | Mar 25, 2013
Company News

NsGene, StemCells deal

StemCells acquired from NsGene a patent family, including U.S. Patent Nos. 6,878,543 and 7,303,912 and European patent application 00973148. The patents claim cell cultures of glial fibrillary acidic protein (GFAP) and intermediate filament marker nestin,...
Items per page:
1 - 10 of 13